Quality & complianceOfficial

Denmark flags supply problems for Fresenius Kabi ceftazidime 1000 mg injection powder

🇩🇰 DKMA · Mon 16 Nov 2026

The Danish Medicines Agency lists Ceftazidim "Fresenius Kabi" 1000 mg as having supply difficulties from November 2026, citing commercial reasons, with no end date known.

The Danish Medicines Agency (DKMA) has published a supply notice for Ceftazidim "Fresenius Kabi" 1000 mg powder for solution for injection, marketed by Fresenius Kabi AB. The notice is dated 16 November 2026 and states that there are current problems with supply of the product.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.